# Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

> **NCT00673010** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **RADIATION:** 131 I-iodine (131-I), 124 I-iodine (124-I)

## Key facts

- **NCT ID:** NCT00673010
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-07
- **Primary completion:** 2025-10-02
- **Final completion:** 2025-10-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673010, "Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00673010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*